Avastimab 100mg Injection

About

Bevacizumab is a highly specialized recombinant humanized monoclonal antibody designed to specifically target and neutralize vascular endothelial growth factor (VEGF). VEGF is a critical signaling protein that plays a pivotal role in angiogenesis, the process by which new blood vessels are formed. Tumors rely heavily on angiogenesis to establish a blood supply, which is essential for their growth, survival, and metastasis. By binding to VEGF, bevacizumab effectively inhibits its biological activity, thereby preventing the formation of new tumor blood vessels and disrupting the existing tumor vasculature. This mechanism of action starves the tumor of vital nutrients and oxygen, leading to significant inhibition of tumor growth and progression. It is a cornerstone in the treatment of various advanced cancers, often used in combination with chemotherapy to enhance therapeutic outcomes and improve patient prognosis by directly interfering with the tumor's ability to sustain itself.

Uses

• Metastatic colorectal cancer
• Non-small cell lung cancer
• Glioblastoma
• Metastatic renal cell carcinoma

Directions For Use

Administer intravenously under the supervision of a qualified healthcare professional. Dosage and infusion rate are determined by the patient's weight and specific cancer type.

Benefits

• Inhibits tumor angiogenesis
• Slows tumor growth and progression
• Improves progression-free survival
• Can be used in combination therapies
• Targets a specific growth factor pathway
• Reduces tumor blood supply

Side Effects

• Hypertension
• Proteinuria
• Hemorrhage
• Thromboembolic events
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Headache
• Diarrhea
• Nausea
• Vomiting
• Neutropenia

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm, including malformations and fetal growth restriction. Effective contraception is required during treatment and for 6 months after the last dose.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Avastimab is excreted in human milk. Potential for serious adverse reactions in breastfed infants.
• Liver - Use with caution in patients with pre-existing liver conditions. Liver function should be monitored regularly during treatment.
• Kidney - Use with caution in patients with pre-existing kidney conditions. Renal function should be monitored, especially for proteinuria.
• Lung - Use with caution in patients with a history of pulmonary hemorrhage or other lung conditions. Monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.